Shots:

• Minovia receives a $20M up front and is eligible to receive ~$420M per product in development- regulatory & commercial milestone for mitochondrial cell therapies caused by mitochondrial dysfunction
• The collaboration is to accelerate the allogeneic mitochondrial cell therapy programs & extend Astellas’ capabilities in mitochondrial biology. The collaboration follows the recent acquisition of Mitobridge and Nanna
• The goal is to treat mitochondrial dysfunction through the transfer of healthy mitochondria to restore the tissues. Currently- Minovia is conducting research- development- and clinical studies with MAT in mitochondrial diseases

    Ref: Astellas | Image: Astellas